Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
INGN 
Inogen Inc (INGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: INGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13
1 Year Target Price $13
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.71% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 196.01M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) 3 | Beta 1.77 | 52 Weeks Range 5.70 - 12.91 | Updated Date 01/9/2026 |
52 Weeks Range 5.70 - 12.91 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.31% | Operating Margin (TTM) -6.98% |
Management Effectiveness
Return on Assets (TTM) -6.21% | Return on Equity (TTM) -13.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 91010040 | Price to Sales(TTM) 0.56 |
Enterprise Value 91010040 | Price to Sales(TTM) 0.56 | ||
Enterprise Value to Revenue 0.26 | Enterprise Value to EBITDA -17.6 | Shares Outstanding 27148482 | Shares Floating 24019619 |
Shares Outstanding 27148482 | Shares Floating 24019619 | ||
Percent Insiders 12.16 | Percent Institutions 73.19 |
Upturn AI SWOT
Inogen Inc
Company Overview
History and Background
Inogen Inc. was founded in 2001 by Daniel J. Hagerty and Aaron C. Harris. The company's mission is to improve the respiratory health of patients worldwide. A key milestone was the development of its first portable oxygen concentrator (POC) in 2004, revolutionizing home oxygen therapy. Inogen went public in 2014.
Core Business Areas
- Direct-to-Consumer (DTC): Inogen sells its portable oxygen concentrators and related accessories directly to patients through its website, direct sales force, and customer service representatives.
- Business-to-Business (B2B): Inogen sells its POCs to home medical equipment (HME) providers, who then rent or sell the devices to patients. This segment also includes sales to government agencies and international distributors.
Leadership and Structure
Inogen's leadership team includes a CEO, CFO, and various executive vice presidents overseeing operations, research and development, and sales and marketing. The company is structured around its direct and indirect sales channels, supported by manufacturing, engineering, and customer support departments.
Top Products and Market Share
Key Offerings
- Inogen One G4: A lightweight and compact portable oxygen concentrator designed for active patients. Competitors include Philips Respironics (SimplyGo), Drive DeVilbiss Healthcare (iGo), and Chart Industries (LifeChoice Activ).
- Inogen One G5: A more powerful portable oxygen concentrator offering higher oxygen output and battery life, suitable for patients requiring more significant oxygen support. Competitors are similar to the G4, with models like the AirSep Freestyle Comfort from Chart Industries.
- Accessories and Consumables: Includes batteries, power supplies, carrying cases, and nasal cannulas, which are recurring revenue streams. Market share for these is tied to the core POC devices.
Market Dynamics
Industry Overview
The respiratory care market, particularly home oxygen therapy, is driven by an aging population and the increasing prevalence of chronic respiratory diseases like COPD. The shift towards portable and user-friendly devices is a significant trend.
Positioning
Inogen is a leader in the portable oxygen concentrator market, particularly with its lightweight and battery-powered devices that offer patients greater freedom and mobility. Its direct-to-consumer model also provides a unique competitive advantage.
Total Addressable Market (TAM)
The global home oxygen therapy market is substantial and growing, with estimates ranging in the billions of dollars. Inogen is well-positioned to capture a significant portion of this market, especially within the portable oxygen concentrator segment where it has a strong brand and product offering.
Upturn SWOT Analysis
Strengths
- Innovative portable oxygen concentrator technology
- Strong brand recognition in the portable oxygen market
- Direct-to-consumer sales model with recurring revenue potential
- Patented technology and intellectual property
Weaknesses
- Reliance on a limited number of core products
- Potential for increased competition and price sensitivity
- Regulatory hurdles and changes in reimbursement policies
- High upfront cost for some consumers
Opportunities
- Expanding into international markets
- Developing new product lines or enhancing existing ones
- Leveraging technological advancements for improved device functionality
- Growing demand for home-based healthcare solutions
Threats
- Intense competition from established medical device companies
- Changes in Medicare and other insurance reimbursement policies
- Economic downturns affecting consumer spending
- Potential for product recalls or manufacturing issues
Competitors and Market Share
Key Competitors
- Philips Respironics (PRSA)
- Drive DeVilbiss Healthcare (Not Publicly Traded)
- Chart Industries (GTLS)
Competitive Landscape
Inogen's advantage lies in its focus on lightweight, user-friendly portable oxygen concentrators and its direct-to-consumer channel. However, competitors like Philips and Chart Industries have broader product portfolios and established distribution networks, posing significant challenges.
Growth Trajectory and Initiatives
Historical Growth: Inogen has historically demonstrated strong growth driven by its innovative products and expanding market penetration. However, recent years have seen slower revenue growth and a decline in profitability.
Future Projections: Analyst projections for Inogen's future growth are mixed, with some expecting a gradual recovery driven by market demand for portable oxygen solutions, while others point to ongoing competitive pressures and operational challenges.
Recent Initiatives: Inogen has focused on optimizing its sales and marketing strategies, improving manufacturing efficiencies, and exploring new product development opportunities to reignite growth and improve profitability.
Summary
Inogen Inc. is a significant player in the portable oxygen concentrator market, known for its innovative technology and direct-to-consumer sales model. While it possesses strengths in product development and brand recognition, the company faces challenges including intense competition, pricing pressures, and inconsistent financial performance. Continued focus on operational efficiency, product innovation, and strategic market expansion will be crucial for future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Inogen Inc. Investor Relations
- Company SEC Filings (10-K, 10-Q)
- Financial Data Providers (e.g., Refinitiv, FactSet)
- Industry Analysis Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inogen Inc
Exchange NASDAQ | Headquaters Goleta, CA, United States | ||
IPO Launch date 2014-02-14 | President, CEO & Director Mr. Kevin R. M. Smith | ||
Sector Healthcare | Industry Medical Devices | Full time employees 766 | Website https://www.inogen.com |
Full time employees 766 | Website https://www.inogen.com | ||
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.